Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Patients are strongly advised to avoid unregulated online sources offering unlicensed compounds
Side Effects & Safety Considerations The adverse event profile of MOUNJARO (tirzepatide) is predominantly gastrointestinal, aligning with the incretin receptor agonist class, with frequency and severity correlating to dose and titration speed.[3][4] Most common reactions include nausea, diarrhea, vomiting, abdominal pain, constipation, dyspepsia, and decreased appetite.[3][4] These effects are typically mild-to-moderate, peak during dose escalation, and lessen over time on a stable dose.[3] If tolerability is significantly compromised, providers should consider delaying escalation or extending the current dose interval
They can also delay stomach emptying and cause nausea, which may result in drinking less fluid GLP-1 medications seem to lower blood pressure in some patients, which can also make patients susceptible to dizzy spells and fainting
At the same time, broad activity can make mechanism assignment more difficult because different tissues may produce similar outcomes through different intermediate pathways
